Answers are grounded in this paper and cite their sources.
Histone acetyltransferase (HAT) inhibitors have potential to target oncogenic transcription networks. Recently, high-potency catalytic and allosteric HAT inhibitors have entered clinical trials. We trace the biological rationale and medicinal chemistry innovations that have allowed for clinical implementation of this emerging drug class. Emphasis is placed on therapeutic principles, including biomarkers that enable exploitation of synthetic lethality in the case of CBP/p300 class, as well as chromosomal amplifications that cause KAT6A overexpression. Structure-based design has enabled modern inhibitors to evolve beyond cofactor mimics to effectively and selectively target cofactor pockets and maintain physiochemical properties for in vivo applications. We highlight emerging areas including targeting noncanonical HATs such as HAT1 to exploit replication stress and the development of heterobifunctional molecules that reposition HATs within their native chromatin environment to engineer desired transcriptional outputs. HAT inhibitors hold promise as monotherapies and in combination with other drug classes to target oncogenic transcription in cancers.
No takes yet. Share an insight, caveat, or question.
Lipchik et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: